Clinomics Inc. (South Korea)

The Company is a Korea-based company engaged in the development of genome diagnostic tests and liquid biopsies. The Company s main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. It is also develops products that diagnoses cancer early with blood. The Company was established on June 21, 2011. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 4, 2020.